公开(公告)号：US20170334894A1

公开(公告)日：2017-11-23

申请号：US15597423

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Yong He ,  Ruichao Shen ,  Xuechao Xing ,  Brett Granger ,  Bin Wang ,  Jun Ma ,  Jing He ,  Jiang Long ,  Guoqiang Wang

IPC: C07D413/12

CPC classification number: C07D413/12 ,  A61K31/42

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20170333399A1

公开(公告)日：2017-11-23

申请号：US15597431

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Xuechao Xing ,  Ruichao Shen ,  Bin Wang ,  Brett Granger ,  Jun Ma ,  Jing He ,  Jiang Long ,  Yong He ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D225/04 ,  C07D213/127 ,  C07D261/08 ,  C07C317/38

CPC classification number: A61K31/42 ,  C07C317/38 ,  C07D213/127 ,  C07D225/04 ,  C07D261/08

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.

公开(公告)号：US20170304272A1

公开(公告)日：2017-10-26

申请号：US15497359

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Brett Granger ,  Jun Ma ,  Jing He ,  Yong He ,  Jiang Long ,  Guoqiang Wang

IPC: A61K31/42 ,  A61K31/422 ,  C07D261/08 ,  C07D413/12

CPC classification number: A61K31/42 ,  A61K31/422 ,  C07D261/08 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US09718851B2

公开(公告)日：2017-08-01

申请号：US14933752

申请日：2015-11-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jay R. Luly ,  Bin Wang ,  Guoqiang Wang ,  Yat Sun Or

IPC: A01N43/04 ,  A61K31/70 ,  C07H19/10 ,  A61K31/7072 ,  A61K45/06 ,  C07H19/06 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068

CPC classification number: C07H19/10 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  C07H19/06

Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R4, R5a, R5b, Rb5, Rb6 and D are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.

公开(公告)号：US11834436B2

公开(公告)日：2023-12-05

申请号：US17228815

申请日：2021-04-13

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:




which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20230143250A1

公开(公告)日：2023-05-11

申请号：US17891436

申请日：2022-08-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Jun Ma ,  Brett Granger ,  Jiang Long ,  Bin Wang ,  Sourav Ghorai ,  Jing He ,  Yong He ,  Xuechao Xing ,  Ruichao Shen ,  Yat Sun Or

IPC: C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

CPC classification number: C07D265/36 ,  C07D277/36 ,  C07C311/29 ,  C07D217/20 ,  C07D471/04 ,  C07D209/18 ,  C07D209/44 ,  C07D417/12 ,  C07D417/04 ,  C07D307/81

Abstract: The present invention provides compounds of Formula (I),




pharmaceutical compositions comprising these compounds and methods of using these compounds to provides a method of modulating a HSD17B13 protein for treatment of metabolic disease or liver condition, The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.

公开(公告)号：US20220356167A1

公开(公告)日：2022-11-10

申请号：US17197399

申请日：2021-03-10

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D417/14 ,  C07D413/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US11345699B2

公开(公告)日：2022-05-31

申请号：US16688429

申请日：2019-11-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: C07D471/04 ,  C07D401/14 ,  C07D417/14 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20220119366A1

公开(公告)日：2022-04-21

申请号：US17228815

申请日：2021-04-13

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US10988458B2

公开(公告)日：2021-04-27

申请号：US16866778

申请日：2020-05-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jiang Long ,  Jun Ma ,  Xuechao Xing ,  Yong He ,  Brett Granger ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D403/12

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).